Abstract
We report the case of a 63-year-old patient with recurrence of acral malignant melanoma after adjuvant immune checkpoint inhibitors (ICI) treatment by PEMBROLIZUMAB complicated with immune-related grade II hepatitis. Rechallenge by combination immune checkpoint (NIVOLUMAB + IPILIMUMAB) led to a relapse of the immune-related hepatitis up to a grade 3. Combination ICI therapy was carried on after introduction of corticosteroid therapy. Here, we present the outcomes of this immune-related adverse event (irAE) and a review of literature on the subject.